IGM Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
IGM Biosciences has a total shareholder equity of $78.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $304.5M and $225.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$218.79m |
| Equity | US$78.95m |
| Total liabilities | US$225.56m |
| Total assets | US$304.51m |
Recent financial health updates
We're Not Very Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Oct 08
Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?
Apr 28We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully
Nov 20We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn
May 10Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Jan 05IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business
Sep 23Recent updates
We're Not Very Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Oct 08IGM Biosciences: Waiting For Godot
Sep 18IGM Biosciences: Unlikely To Move The Needle Again In 2024
May 12Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?
Apr 28IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points
Feb 12We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully
Nov 20We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn
May 10Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Jan 05IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business
Sep 23IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates
Aug 29IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M
Aug 08We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Jun 09IGM Biosciences: Interesting Science, Poor Trial Data
Feb 23Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Sep 07IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
May 25Financial Position Analysis
Short Term Liabilities: IGMS's short term assets ($229.6M) exceed its short term liabilities ($44.0M).
Long Term Liabilities: IGMS's short term assets ($229.6M) exceed its long term liabilities ($181.6M).
Debt to Equity History and Analysis
Debt Level: IGMS is debt free.
Reducing Debt: IGMS had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IGMS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IGMS has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 27.2% each year.